Cargando…

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer

Prostate cancer (PCa) has become the most common cancer among males in Europe and the USA. Adoptive immunotherapy appears a promising strategy to control the advanced stages of the disease by specifically targeting the tumor, in particular through chimeric antigen receptor T (CAR-T) cell therapy. De...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montagner, Isabella Monia, Penna, Alessandro, Fracasso, Giulio, Carpanese, Debora, Dalla Pietà, Anna, Barbieri, Vito, Zuccolotto, Gaia, Rosato, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349573/ https://www.ncbi.nlm.nih.gov/pubmed/32498368 http://dx.doi.org/10.3390/cells9061382

Ejemplares similares

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
por: Zuccolotto, Gaia, et al.
Publicado: (2014)

Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2015)

Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines
por: Dalla Pietà, Anna, et al.
Publicado: (2021)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
por: Montagner, Isabella Monia, et al.
Publicado: (2014)

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Hyaluronan as an immunological adjuvant: a novel application for an ancient molecule
por: Carpanese, D., et al.
Publicado: (2023)

CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
por: Lu, Shi‐Jiang, et al.
Publicado: (2021)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer
por: Wang, Fangming, et al.
Publicado: (2022)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
por: Sommaggio, Roberta, et al.
Publicado: (2020)

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors
por: Turrini, Riccardo, et al.
Publicado: (2017)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
por: Zhang, Qing, et al.
Publicado: (2018)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”
por: Zhang, Qing, et al.
Publicado: (2019)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
por: Walcher, Lia, et al.
Publicado: (2021)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

A Review on the Current State and Future Perspectives of [(99m)Tc]Tc-Housed PSMA-i in Prostate Cancer
por: Brunello, Sara, et al.
Publicado: (2022)

Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
por: Ao, Xiang, et al.
Publicado: (2019)

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_658o63bstkct2lmhavbsitlq2m